. 2016 Dec;359(3):471–481. doi: 10.1124/jpet.116.236547

TABLE 3 .

Effects on secondary measures following oral drug administration (PD analysis set)

Parameter	Statistic	PBO  (n = 37)	OXY IR 30 mg (n = 37)	OXY IR 60 mg (n = 37)	ELX 100 mg (n = 35)	ELX 300 mg (n = 36)	ELX 1000 mg (n = 35)
Overall Drug Liking VAS
At 12 h	Mean (S.D.)	51.4 (13.6)	77.3 (17.5)	77.9 (19.2)	50.5 (19.7)	47.2 (24.9)	49.8 (24.0)
	Median	50.0	81.0	78.0	50.0	50.0	50.0
	P value^a	—	^***	^***	^{††† ‡‡‡}	^{††† ‡‡‡}	^{††† ‡‡‡}
Take Drug Again VAS
At 12 h	Mean (S.D.)	15.1 (30.9)	79.4 (25.7)	74.3 (30.5)	18.0 (33.6)	22.5 (30.7)	26.7 (34.1)
	Median	0.0	86.0	90.0	0.0	0.5	2.0
	P value^a	—	^***	^***	^{††† ‡‡‡}	^* ^{††† ‡‡‡}	^{††† ‡‡‡}
Bad Effects VAS
E_max	Mean (S.D.)	8.8 (21.3)	23.4 (29.8)	40.5 (37.9)	13.3 (29.3)	26.9 (28.3)	23.1 (30.5)
	Median	0.0	3.0	28.0	0.0	14.5	11.0
	P value^a	—	**	^***	NS	**	^*
Pupil diameter
MPC	Mean (S.D.)	0.8 (0.7)	2.2 (0.7)	2.6 (0.8)	0.7 (0.5)	0.9 (0.5)	0.9 (0.5)
	Median	0.7	2.0	2.5	0.8	0.8	0.9
	P value^a	—	^***	^***	^{††† ‡‡‡}	^{††† ‡‡‡}	^{††† ‡‡‡}

ELX, eluxadoline; MPC, maximum pupil constriction; NS, not significant; OXY IR, oxycodone immediate release; PBO, placebo.

^{^a}

P values are for pairwise comparisons of median differences between treatments, assessed using the Wilcoxon signed-rank test.

Significant versus PBO (P < 0.05); **significant versus PBO (P < 0.01);

^***

significant versus PBO (P < 0.0001); ^†††significant versus OXY IR 30 mg (P < 0.0001);

^{^‡‡}

significant versus OXY IR 60 mg (P < 0.01); ^‡‡‡significant versus OXY IR 60 mg (P < 0.0001).